对照组除未加盐酸替罗非班外，其他治疗同治疗组。
The treatment in the control group was the same as that in the treatment group except that no tirofiban was infused.
结论：ACS患者应用国产盐酸替罗非班安全、有效。
Conclusion: Homemade tirofiban is safety and effective in treating patients with ACS.
对照组除未加盐酸替罗非班外，其他治疗同替罗非班组。
The treatment in the control group was the same as that in the treatment group except the tirofiban.
铩急性心肌梗死；血栓抽吸；替罗非班；经皮冠状动脉介入；护理。
Acute myocardial infarction; Thrombus aspiration; Tirofiban; Percutaneous coronary intervention; Nursing.
结论替罗非班在急性心肌梗死的急诊介入治疗过程中是有效的和安全的。
Conclusion Tirofiban to emergency intervention therapy in paitent with acute myocardial infarction is effective and safe.
目的：观察盐酸替罗非班对平板运动试验中ST段抬高患者TIMI血流分级的影响。
Objective:To evaluate the effect of tirofiban on TIMI flow in patients with ST segment elevating of treadmill exercise test.
结论：ST段抬高急性心肌梗死患者在急诊pci术前应用盐酸替罗非班是安全有效的。
Conclusion: ST-segment elevation acute myocardial infarction patients before surgery in the emergency PCI tirofiban hydrochloride is safe and effective.
结论急诊pci术期间短程应用替罗非班能安全、有效地改善冠状动脉血流和心肌灌注。
Conclusions Using of tirofiban within short periods can safely improve coronary flow and myocardial perfusion during PCI.
目的探讨替罗非班对急性冠状动脉综合征患者对抗凝肝素剂量及血小板计数和功能的影响。
Objectives To explore the effects of tirofiban on dose of heparin and platelet aggregation in the patients with acute coronary artery syndrome.
目的：分析冠状动脉介入治疗急性ST段抬高型心肌梗死中应用替罗非班对内皮细胞功能的影响。
Objective To investigate the effects of tirofiban on endothelial cell function in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
目的探讨替罗非班在急诊经皮冠状动脉介入(PCI)术后患者中的临床疗效、护理措施及经验。
Objective To explore clinical efficacy, nursing measures and experience of tirofiban on the emergency percutaneous coronary intervention (PCI) in patients.
目的：探讨下肢深静脉血栓介入治疗中形成急性血栓，应用新型抗血小板药物替罗非班的临床价值。
Objective: To study the application value of neotype antiplatelet drug tirofiban in the interventional therapy of lower extremity deep venous thrombosis after acute thrombosis was formed.
结论联合应用替罗非班可降低抗凝肝素剂量，显著抑制血小板聚集，并呈降低降低血小板数的趋势。
Conclusions Addition to the conventional therapies with anti-platelets and anti-coagulation, tirofiban can reduce the dose of heparin, inhibit platelet aggregation and decrease the platelets number.
目的：评估替罗非班用于急性ST段抬高心肌梗死患者急诊冠状动脉介入治疗时的安全性及临床疗效。
Objective To assess the safety and values of tirofiban in the patients with acute ST-elevation myocardial infarction during emergency percutaneous coronary intervention.
目的探讨老年急性心肌梗死(ami)患者急诊经皮冠状动脉介入治疗(pci)联合应用替罗非班的安全性。
Objective To assess safety of tirofiban in elderly patients with acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (PCI).
结论冠状动脉内或静脉内应用替罗非班均能快速有效地降低冠状动脉局部及静脉内的PAR，且不增加出血风险。
Conclusion Both intracoronary and intravenous application of tirofiban can effectively decrease PAR in coronary artery and peripheral vessel, and may not increase the risk of bleeding.
目的比较冠状动脉内与静脉应用替罗非班对急性冠状动脉综合征(ACS)患者冠状动脉和静脉内血小板聚集率(par)的影响。
Objective To investigate the effects of intracoronary and intravenous application of tirofiban on platelet aggregation rate (PAR) in patients with acute coronary syndrome (ACS).
然而，却有相当比例的患者的治疗使用了替非罗班——具有阿昔单抗的部分药理学特性。
However, a large proportion of patients in the community are treated with eptifibatide, an agent that shares some but not all pharmacological properties with abciximab.
然而，却有相当比例的患者的治疗使用了替非罗班——具有阿昔单抗的部分药理学特性。
However, a large proportion of patients in the community are treated with eptifibatide, an agent that shares some but not all pharmacological properties with abciximab.
应用推荐